NOVEL-1st: an observational study to assess the safety and efficacy of nilotinib in newly diagnosed patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase in Taiwan.
Hwang WL, Chen TC, Lin HY, Chang MC, Hsiao PC, Bai LY, Kuo CY, Chen YC, Liu TC, Gau JP, Wang PN, Hwang WS, Kuo MC, Liu CY, Liu YC, Ma MC, Su NW, Wang CC, Wu YY, Yao M, Yeh SP, Cheng HW, Lee YM, Ku FC, Tang JL.
Hwang WL, et al. Among authors: cheng hw.
Int J Hematol. 2022 May;115(5):704-712. doi: 10.1007/s12185-022-03311-1. Epub 2022 Feb 25.
Int J Hematol. 2022.
PMID: 35212915
The NOVEL-1st study was a non-interventional, multi-center study collecting long-term safety and effectiveness data in patients with newly diagnosed and untreated Ph(+) CML-CP receiving nilotinib. ...Nilotinib is effective and well-tolerated in patients with newly diagnose …
The NOVEL-1st study was a non-interventional, multi-center study collecting long-term safety and effectiveness data in patients with …